In today’s recent session, 2.48 million shares of the Moderna Inc (NASDAQ:MRNA) have been traded, and its beta is 1.86. Most recently the company’s share price was $26.15, and it changed around -$0.52 or -1.94% from the last close, which brings the market valuation of the company to $10.11B. MRNA at last check was trading at a discount to its 52-week high of $145.74, offering almost -457.32% off that amount. The share price’s 52-week low was $23.15, which indicates that the recent value has risen by an impressive 11.47% since then.
Moderna Inc stock received a consensus recommendation rating of Hold, based on a mean score of 2.86. If we narrow it down even further, the data shows that 1 out of 27 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 17 recommended MRNA as a Hold, whereas 5 deemed it a Buy, and 3 rated it as Underweight. Moderna Inc is expected to report earnings per share of -2.95 for the current quarter.
Moderna Inc (NASDAQ:MRNA) trade information
Instantly MRNA has been showing red trend so far today with a performance of -1.94% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 28.72 on recent trading dayincreased the stock’s daily price by 8.95%. The company’s shares are currently down -37.10% year-to-date, but still down -7.06% over the last five days. On the other hand, Moderna Inc (NASDAQ:MRNA) is 10.58% up in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $47.5, which translates to bulls needing to increase their stock price by 44.95% from its current value. Analyst projections state that MRNA is forecast to be at a low of $45 and a high of $50.
Moderna Inc (MRNA) estimates and forecasts
The year-over-year growth rate is expected to be -36.00%, down from the previous year.
Consensus estimates provided by 13 financial analysts predict the company will bring in an average of 116.26M in revenue for the current quarter. 13 analysts expect Moderna Inc to make 1.15B in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 241M and 1.86B respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -51.76%. Forecasts for the next quarter put sales growth at -38.01%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -42.94%. Moderna Inc earnings are expected to increase by -8.51% in 2025, but the outlook is positive 20.72% per year for the next five years.
MRNA Dividends
Moderna Inc’s next quarterly earnings report is expected to be released in July.
VANGUARD GROUP INC, with 10.3028% or 39.56 million shares worth $4.7 billion as of 2024-06-30, holds the second largest percentage of outstanding shares.
